On the Watch
Drug shortages have big impact on patient care
Drug shortages remain a serious problem for patient safety, according to newly published results from a survey of pharmacy directors. Nearly half of the responding directors reported adverse events at their facilities resulting from drug shortages
On the Watch
Holes in the drug market place | How to overcome these obstacles
Complex diseases present complex challenges for researchers, clinicians, drug manufacturers, and FDA for a variety of reasons. The impact, however, is felt at the patient level, particularly when there are no FDA-approved treatments.
On the Watch
Drugs in Context: Oxytrol goes over-the-counter
Although the Oxytrol transdermal patch has been available as a prescription product since 2003, in January 2013 FDA approved Oxytrol for Women as an over-the-counter product
previous pause next
  • Drugs in Context: Farxiga (dapagliflozin)

  • Antidiabetic drugs are considered to be first-line treatment options for individuals with type 1 and type 2 diabetes mellitus. It is estimated that type 2 diabetes affects about 24 million persons in the United States. Over time high blood levels can lead to complications such as heart disease, kidney damage, or blindness.1 When it comes to the treatment of type 2 diabetes individuals have the option of using oral hypoglycemic agents, compared to individuals with type 1 diabetes that requires insulin therapy.
  • National, state data show ongoing efforts needed help fight healthcare-associated infections

  • Progress has been made in the effort to eliminate infections that commonly threaten hospital patients, but more work is needed to improve patient safety, according to 2 reports released by the Centers for Disease Control and Prevention (CDC).
  • Telephonic MTM can benefit lower risk Medicare patients after hospital discharge

  • Low-risk Medicare patients entering home healthcare and receiving a telephonic medication therapy management (MTM) consultation by a pharmacist were three times less likely to be hospitalized within the next 2 months, while those at greater risk saw no benefit, according to a study in Health Services Research.
  • FDA approves first naloxone treatment to be given by caregivers to reverse opioid overdose

  • FDA has approved naloxone hydrochloride injection (Evzio; Kaléo, formerly Intelliject) for emergency treatment when opioid overdose is known or suspected because of respiratory and/or central nervous system depression.
  • IV nitroglycerin shortage concerning, but manageable

  • Although every drug shortage is a concern to healthcare professionals, the shortage of IV nitroglycerin that the New York Times first reported on, is especially concerning: Unlike with the IV saline shortage, in dealing with refractive chest pain and hypertensive crisis in the emergency room there is no substitute or direct alternative for IV nitroglycerin
More Articles